COMPASS Pathways plc (CMPS)
| Previous Close | 10.90 |
| Open | 11.00 |
| Bid | 10.97 x 2200 |
| Ask | 11.00 x 800 |
| Day's Range | 10.68 - 11.00 |
| 52 Week Range | 6.54 - 49.51 |
| Volume | |
| Avg. Volume | 307,345 |
| Market Cap | 466.707M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.94 |
| Earnings Date | May 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 68.00 |
- Zacks
Wall Street Analysts See a 781% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 781.4% in COMPASS Pathways PLC Sponsored ADR (CMPS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- GlobeNewswire
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
Hear Professor David Hellerstein talk about the study Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today presented positive data from the largest randomised, controlled, double-blind study of psilocybin therapy ever completed, at the Ameri
- Simply Wall St.
Could The COMPASS Pathways plc (NASDAQ:CMPS) Ownership Structure Tell Us Something Useful?
The big shareholder groups in COMPASS Pathways plc ( NASDAQ:CMPS ) have power over the company. Insiders often own a...
